| Rich66 |
10-18-2011 10:39 PM |
halozyme: injection Herceptin
http://www.signonsandiego.com/news/2...cancer-drug-r/
Quote:
Roche's government-approved Herceptin is normally delivered intravenously to breast cancer patients in sessions lasting about 30 minutes. The new formulation using Halozyme's patented enzyme is being tested as a subcutaneous injection that can be administered in about five minutes.
Shares of Halozyme rose $1.28, or more than 20 percent, to $7.48 following the announcement.
Women who participated in the Phase 3 trial were in the early stages of a more aggressive form of breast cancer involving tumors that produce larger amounts of human epidermal growth factor receptor 2 proteins because of a genetic mutation.
Those who received the injection version of Herceptin experienced therapeutic results that were similar to those experienced by participants who were given an intravenous infusion of the drug, Halozyme said.
No new safety issues were reported by researchers, and adverse events involving the injected drug were similar to those associated with the intravenous version, the company said.
|
|
